Again, maybe NGIO has $300MM+ potential, but until someone ponies up a huge chuck of $ to purchase a portion of the company and give it that value, it is just potential like many of the GNBT prospects.

Don't get me wrong, I think there is value there. However, this kind of valuation hinges on someone seeing a payday in the near future. Might need Phase II results?

Dunno, I'm not an expert on drug companies... will be pleasantly and jubilantly surprised if Joe is able to attain that sort of $!